MDMA for PTSD Showing Promising Outcomes for Patients in MAPS Phase 3 Trials
“In the pharmaceutical drug development community, this is what you dream about.”
Mental Health - Page 4
Noribogaine is More Effective Than Fluoxetine in Reducing Depressive Symptoms in Rat Model
Three doses of fluoxetine were needed to elicit the effects of one dose of noribogaine.
Antidepressant-Like Effect with A Single Dose of Ibogaine and Noribogaine in Rats
This is the first preclinical study to examine the anti-depressive effects of ibogaine and noribogaine.
The Structure and Function of the Serotonin 5-HT2C Receptor
5-HT2C has a role in the psychedelic effect. Understanding it is essential for harnessing the full benefits of nature’s chemical cocktails.
Psilocybin Superior to Ketamine for Prolonged Antidepressant-Like Effects (Rodent Model)
Results support the idea that serotonin 5-HT2A receptor-directed therapeutic strategies may be superior to ketamine-based treatments for depression.
Psilocybin Mindfulness Negatively Correlated with 5-HT2A Binding, Study Finds
Results hint at a possible mechanism for the persistent effect that psilocybin has on mindfulness.
Psychedelics May Aid in Deprogramming Addiction
Recent evidence suggests psychedelics may significantly improve addiction treatment outcomes.
Emotional Adjustment: The Modulatory Influence of Psilocybin on the Amygdala
Recent research suggests that psilocybin causes changes in amygdala activity opposite to those seen in conventional antidepressant treatment.
Positive Effects of Single-Dose Psilocybin Last Nearly 5 Years
After 4.5 years, 60-80% of the study participants with life-threatening cancer still experienced significantly decreased anxiety or antidepressant effects.
The Medical University of South Carolina is Launching a Psychedelic Research Center
Scheduled to open in 2021, the new center will study the therapeutic potential of MDMA, psilocybin, DMT, and mescaline.